Grigory Viktorovich Tochilnikov

Grigory Viktorovich Tochilnikov

Auto-generated profile, based on publicly available information

Grigory Viktorovich Tochilnikov

NMRC of Oncology named after N.N. Petrov of MoH of Russia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2021 in Andrologia
Verified
Journal Article
Open access
PDF file
VAValerij A. Alexandrov
Valerij A. Alexandrov
GTGrigory V. Tochilnikov
Grigory V. Tochilnikov
NZNadezhda T. Zhilinskaya
Nadezhda T. Zhilinskaya
EGEkaterina A. Gubareva
Ekaterina A. Gubareva
VRVladimir A. Romanov
Vladimir A. Romanov
ASAlexander Semenov
Alexander Semenov
Benign prostatic hyperplasia (BPH) is a common chronic disease in ageing men. Synthetic inhibitors of 5α-reductase commonly used in BPH treatment have limited effectiveness and may cause side effects. Evaluation of iodised serum milk protein and lycopene therapeutic effect in rat BPH model was the aim of the present study. BPH was induced in male Wistar rats by surgical castration and subsequent testosterone administrations (25 mg/kg, 7 injections). Rats with induced BPH received lycopene (5 mg/kg), iodised serum milk protein (200 µg/kg) or their combination for 1 month daily. The efficacy of the treatment was evaluated by the prostate weight, prostatic index and ventral lobe epithelium thickness. In lycopene and iodised serum milk protein-treated rats, prostate weight and prostatic index were significantly reduced compared to control group; and lycopene and iodised serum milk protein used in combination yielded an additive effect. Thus, further investigation of combined supplementation with micronutrients and plant-derived substances in BPH models may help to find new opportunities or its safe and effective treatment.

29 June 2023 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
ВАВ. А. Александров
В. А. Александров
ASA. N. Stukov
A. N. Stukov
YZYu. G. Zmitrichenko
Yu. G. Zmitrichenko
GTG. V. Tochilnikov
G. V. Tochilnikov
Background. Current treatment of HER2-positive metastatic breast cancer (BC) is based on the use of anti-HER2 blockers as pathogenic drugs, as well as the search for the optimal combination of anticancer drugs with different mechanisms of action. The potential activity of chlonisol in HER2+ ВС is of great interesting. The aim of the study was to evaluate the antitumor effect of 2-[3-(2-chloroethyl)-3-nitrosouriedo]-1,3-propanediol (chlonisol) on the growth of spontaneous mammary tumors in HER-2/neu transgenic FVB/N mice. Material and Methods. A prospective study used 5-month-old female mice with HER2-positive mammary tumors. Of these animals, ten pairs with almost the same size of tumors were formed (respectively, for the control group and the chlonisol treatment group). Chlonisol was administered at a dose of 20 mg/kg intraperitoneally, once. The animals were followed up for 30 days. Results. In all ten pairs of mice, chlonisol showed a significant antitumor effect, up to a complete temporary regression of the tumor. When summing the comparative results of all ten pairs of animals, the inhibition of tumor growth (ITG) in the chlonisol treatment group was 90-97 % (p<0.0001), and the area under the kinetic curve of tumor growth was 13.6 times less than in the control group (p<0.0001), thus indicating a significant effect. Conclusion. Chlonisol has a high therapeutic activity by inhibiting the growth of spontaneous HER2-positive breast tumors in FVB/N mice.

22 July 2024 in Reviews on Clinical Pharmacology and Drug Therapy
Verified
Journal Article
Open access
OVOlesya Vasilyeva
Olesya Vasilyeva
DKDmitrii Al. Kachanov
Dmitrii Al. Kachanov
ASAlexander Nikolaevich Stukov
Alexander Nikolaevich Stukov
GTGrigory Viktorovich Tochilnikov
Grigory Viktorovich Tochilnikov
APAndrey Vladislavovich Pavlysh
Andrey Vladislavovich Pavlysh
БМБеляев Алексей Михайлович
Беляев Алексей Михайлович
Currently, the targeted delivery of anticancer drugs can significantly increase the effectiveness of therapy, reduce the side effects of systemic chemotherapy, and improve the quality of patients with cancer. This review aimed to summarize data about the domestic antitumor drug 2,4-bis(1-aziridinyl)-6-(2,2-dimethyl-5-hydroxymethyl-1,3-dioxan-5-yl)amino-1,3,5-thriazine (dioxadet), its nanoforms, possibilities of its use in the clinic, and main antitumor nanodrugs clinically introduced in recent years. Library databases (eLibrary, PubMed, CyberLeninka, ResearchGate, Springer, Wiley Online Library, and Elsevier) were searched for relevant information. The literature review summarizes data on the preclinical trials of dioxadet and provides information on its nanoforms, such as nanogels, nanodiamonds, silica particles, and copolymers with lactic and caproic acids. New drug nanoforms open up opportunities to reduce drug side effects and systemic toxicity, maintain optimal therapeutic concentrations, increase the drug circulation time in the blood, and control its release. The possibility of using chemopreparation cytotoxic doses is the main advantage of new nanodrugs. To date, approximately 20 antitumor nanodrugs have been introduced in clinical practice, and some nanodrugs are undergoing preclinical trials or are in various phases of clinical trials. Thus, the development of a new effective nanoform, i.e., dioxadet, makes it possible to ensure targeted drug delivery in higher cytotoxic doses to target cells, increase selective action, and reduce cytostatic toxicity to normal cells.

1 January 2022 in Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science)
Verified
Journal Article
Closed access
YMYa.G. Murazov
Ya.G. Murazov
ASA.N. Stukov
A.N. Stukov
IZIu.G. Zmitrichenko
Iu.G. Zmitrichenko
GTG.V. Tochilnikov
G.V. Tochilnikov

23 March 2024 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
ВАВ. А. Александров
В. А. Александров
ASA. N. Stukov
A. N. Stukov
YZYu. G. Zmitrichenko
Yu. G. Zmitrichenko
OBO. A. Belyaeva
O. A. Belyaeva
GTG. V. Tochilnikov
G. V. Tochilnikov
Background. In patients with HER2-positive breast cancer (HER2+ BC), as a result of targeted anti-HER2 therapy, the remission period is significantly prolonged. However, resistance to therapy often develops, especially in relation to brain metastases. In the search for effective additional drugs in combination therapy, it is advisable to study the antitumor effect of lomustine (CCNU) in HER2+ BC. Lomustine is not targeted, but is used to treat brain metastases, because it is known as one of the standard remedies for glioblastomas.Aim. Evaluate the inhibitory activity of lomustine on the growth of spontaneous HER2+ BC in female FVB/N mice.Materials and methods. Transgenic mice HER2+ aged 5–6 months were used, from which seven pairs of animals were selected (for control and treatment with lomustine) with spontaneous mammary tumors of the same size in each pair. Lomustine was administered once at a dose of 50 mg/kg (orally by gavage) followed by a 30-day follow-up. The criteria for evaluating the antitumor effect were ITG % (inhibition of tumor growth), as well as TGI (tumor growth index), calculated by the ratio of the area (S) under the kinetic curve of tumor growth in the group of animals treated with lomustine (SE ) to control (SC ). With such a comparison in the control, TGI will always be 100 %.Results. During the observation period, the volume of ВС in the control (solvent administration) increased 8-fold, while in mice treated with lomustine, the tumors regressed significantly. ITG after treatment with lomustine was 78–92 % (p = 0.007–0.0006, to control). The total mean S significantly differed by 5.6 times when comparing the control and lomustine groups and TGI in mice in the lomustine group was 18.8 %, while in the control it was 100 % (p = 0,0006).Conclusion. Lomustine exhibits a pronounced inhibitory effect on the growth of spontaneous HER2+ ВС in FVB/N transgenic mice. The results indicate the advisability of using lomustine in patients with HER2+ ВС complicated by cerebral metastases.

27 September 2021 in Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Open access
PDF file
IMI. G. Murazov
I. G. Murazov
ASA. N. Stukov
A. N. Stukov
IZIu. G. Zmitrichenko
Iu. G. Zmitrichenko
ANA. O. Niuganen
A. O. Niuganen
GTG. V. Tochilnikov
G. V. Tochilnikov
TST. Yu. Semiglazova
T. Yu. Semiglazova
Background. The arsenal of antitumor drug therapy for melanoma brain metastases is limited. The search and study of new agents capable to penetrate the blood-brain barrier and provide a therapeutic effect against intracranial tumors remains an unmet clinical need. The aim is to evaluate the antitumor activity of the domestic derivative of nitrosoalkylureas, chlonisol, in mice with intracranially transplanted syngeneic B16 melanoma. Methods. The experiment was carried out in 18 female inbred C57BL/6 mice. After intracranial tumor transplantation, performed according to modified technique, the animals were randomized into two groups: I. Control (n = 10) – the animals were injected with normal saline 10 ml/kg intraperitoneally; II. Chlonisol (n = 8) – the animals were treated with the test compound at a dose of 15 mg/kg in normal saline intraperitoneally. The single administration of normal saline and chlonisol was performed 24 hours after tumor transplantation. The end point of the study was overall survival (OS) of the animals. Results. Compared with the control group, administration of chlonisol significantly increased the median OS of mice from 13 to 18 days (log rank test, p = 0.0005). Chlonisol significantly decreased the risk of death by 71 % compared with the control group (HR = 0.29; 95 %CI 0.10–0.82). By the 15th day after intracranial transplantation of B16 melanoma, all 10 mice in the control group died from intracerebral tumors (100 %), whereas in the chlonisol group only 2 out of 8 (25 %) mice died (Fisher's exact test, p = 0.0015). Conclusion. Despite the exploratory nature of the present study, it provides a good starting point for further research of chlonisol in brain tumors.